This article is more than 5 years old. Information may no longer be current.
Top takeaways from Heart in Diabetes 2019
Click Here to Manage Email Alerts
Endocrine Today has compiled a list of the top five news reports posted from Heart in Diabetes, held July 12-14, 2019, in Philadelphia.
Healio.com/Endocrinology readers were interested in the effects of hypoglycemia on cognitive and cardiovascular disease, metformin use in type 1 diabetes and more.
All content from the meeting is available under the Meeting News tab.
Severe hypoglycemia indicates cardiovascular, cognitive danger
Severe hypoglycemic events can present cardiovascular and cognitive risks, and hypoglycemia should signal a call to action for physicians treating the patients with diabetes.
Metformin shows promise for vascular health in adolescents with type 1 diabetes
Adolescents with type 1 diabetes already show early hallmarks of cardiovascular disease, and an intervention with a commonly used type 2 diabetes therapy can improve their vascular health and reduce future CV risk.
Weight loss mediates CV damage of fatty liver in diabetes
Nonalcoholic fatty liver disease is an “unrecognized epidemic” among people with type 2 diabetes.
Trial data highlight need for redefined guidelines for older adults with diabetes
Older adults with type 2 diabetes can derive meaningful cardiovascular and renal benefits from newer antihyperglycemic agents, and data from several large CV outcomes trials suggest that treatment guidelines for this population should be redefined to reflect such findings.
Ethnicity, age, sex influence CV risk in type 2 diabetes
The growing global burden of type 2 diabetes and cardiovascular disease disproportionately affects people living in countries experiencing large social transitions, with women and those diagnosed before age 40 years more likely to experience worse disease outcomes.